High-density lipoproteins and cardiovascular disease: 2010 update

References

• Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can. J. Cardiol.25(10), 567–579 (2009).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation118, 2243–2251 (2008).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care30(1), 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet364(9438), 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res.95(8), 764–772 (2004).
   PubMed Web of Science ®Google Scholar
• Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med.54, 321–341 (2003).
   PubMed Web of Science ®Google Scholar
• Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ. Res.98, 1352–1364 (2006).
   PubMed Web of Science ®Google Scholar
• Argraves KM, Gazzolo PJ, Groh EM et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem.283, 25074–25081 (2008).
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr. Opin. Lipidol.20(3), 197–205 (2009).
   PubMed Web of Science ®Google Scholar
• Awan Z, Al Waili K, Alrasadi K, Genest J. Treatment of low high density lipoprotein cholesterol. Can. J. Cardiol.24, 27c–31c (2008).
   Google Scholar
• Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res.50(Suppl.), S189–S194 (2009).
   PubMed Web of Science ®Google Scholar
• Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol.6(7), 455–463 (2009).
   PubMed Web of Science ®Google Scholar
• Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest.115(5), 1333–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest.116(4), 1052–1062 (2006).
   PubMed Web of Science ®Google Scholar
• Denis M, Haidar B, Marcil M, Krimbou L, Genest J. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP biding cassette A1 (ABCA1). J. Biol. Chem.279, 7384–7394 (2004).
   PubMed Web of Science ®Google Scholar
• Haidar B, Denis M, Marcil M, Krimbou L, Genest J. Apolipoprotein A-I activates cellular camp signaling through the ABCA1 receptor. Evidence for molecular interactions between ABCA1 receptor and G protein. J. Biol. Chem.279, 9963–9969 (2004).
   Google Scholar
• Wu Z, Gogonea V, Lee X et al. The double super helix model of high density lipoprotein. J. Biol. Chem.284(52), 36605–36619 (2009).
   Google Scholar
• Vedhachalam C, Duong PT, Nickel M et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem.282(34), 25123–25130 (2007).
   PubMed Web of Science ®Google Scholar
• Hassan HH, Denis M, Lee DY et al. Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J. Lipid Res.48(11), 2428–2442 (2007).
   Google Scholar
• Hassan HH, Bailey D, Lee DY et al. Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J. Biol. Chem.283(17), 11164–11175 (2008).
   Google Scholar
• Bailey D, Ruel I, Hafiane A, Cochrane H et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. doi:10.1194/jlr.M001875 (2009) (Epub ahead of print).
   Google Scholar
• Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome and risk of Type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab.91(8), 2906–2912 (2006).
   PubMed Web of Science ®Google Scholar
• Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. Genetic–epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp. Gerontol.44(3), 136–160 (2009).
   Google Scholar
• Alrasadi K, Ruel IL, Marcil M, Genest J. Functional mutations in the ABCA1 gene in subjects of French Canadian descent with HDL deficiency. Atheroscler.188, 281–291 (2006).
   Google Scholar
• Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science305(5685), 869–872 (2004).
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest.114(9), 1343–1353 (2004).
   PubMed Web of Science ®Google Scholar
• Lee C-Y, Vincent J, Lesimple A et al. Increased sphingomyelin content of HDL impairs HDL biogenesis and maturation in human Niemann–Pick disease type B. J. Lipid Res.47, 322–332 (2006).
   Google Scholar
• Lee C-Y, Tamura T, Rabah N et al. The carboxyl-terminal disulfide bond of acid sphingomyelinase is critical to its secretion and enzymatic function. Biochemistry46(51), 14969–11497 (2007).
   Google Scholar
• Dastani Z, Pajukanta P, Marcil M et al. Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. Eur. J. Hum. Genet.18(3), 342–347 (2009).
   Google Scholar
• Iatan I, Dastani Z, Do R et al. Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates HDL cholesterol levels. Circ. Cardiovasc. Genet.2(5), 467–475 (2009).
   Google Scholar
• Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the r-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest.107, 1423–1429 (2001).
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med.335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• No authors listed. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial investigators. N. Engl. J. Med.336(3), 153–162 (1997).
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• No authors listed. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital. Heart J.1(12), 810–820 (2000).
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA et al.; GREACE collaborative group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin.20(5), 627–637 (2004).
   PubMed Web of Science ®Google Scholar
• Serruys PW, De Feyter PJ, Benghozi R, Hugenholtz PG, Lesaffre E. The Lescol Intervention Prevention Study (LIPS): a doubleblind, placebo-controlled, randomized trial of the longterm effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int. J. Cardiovasc. Intervent.4(4), 165–172 (2001).
   PubMedGoogle Scholar
• Larosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction – the IDEAL study: a randomized controlled trial. JAMA294(19), 2437–2434 (2005).
   PubMed Web of Science ®Google Scholar
• MacMahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis.10, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand.223, 405–418 (1988).
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50 anniversary review. J. Int. Med.258, 94–114 (2005).
   PubMed Web of Science ®Google Scholar
• Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol.17, 631–636 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361(22), 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation102(1), 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med.,317(20), 1237–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Abourbih S, Filion KB, Joseph L et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med.122(10), 962.e1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J. Lipid Res.34(8), 1255–1274 (1993).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol.23(2), 160–167 (2003).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357(21), 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman JA et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet370, 1907–1914 (2007).
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman AJ, Jin B et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther.84(6), 679–683 (2008).
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J.157(2), 352–360.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am. J. Cardiol.104(1), 82–91 (2009).
   PubMed Web of Science ®Google Scholar
• Stroes ES, Kastelein JJ, Bénardeau A et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin–angiotensin–aldosterone system in rats. Br. J. Pharmacol.158(7), 1763–1770 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM et al.; dal-OUTCOMES committees and investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J.158(6), 896–901 (2009).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Pencina MJ, Robins SJ et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation120(24), 2414–2420 (2009).
   PubMed Web of Science ®Google Scholar
• Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest.116(12), 3090–3100 (2006).
   PubMed Web of Science ®Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA298(7), 786–798 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA290(17), 2292–2300 (2003).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Grégoire J, L’Allier PL et al.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA297(15), 1675–1682 (2007).
   PubMed Web of Science ®Google Scholar
• Meyer P, Nigam A, Marcil M, Tardif J-C. The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. Curr. Atheroscler. Rep.11(5), 329–333 (2009).
   Google Scholar
• Wool GD, Vaisar T, Reardon CA, Getz GS. An ApoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res.50(9), 1889–1900 (2009).
   Google Scholar
• Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta1735(1), 1–19 (2005).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci.30(11), 570–580 (2009).
   PubMed Web of Science ®Google Scholar
• Masson D, Koseki M, Ishibashi M et al. Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol.29(12), 2054–2060 (2009).
   PubMed Web of Science ®Google Scholar
• Ganesan A, Benning L, Golub ET et al. Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. AIDS Res. Ther.6, 13 (2009).
   PubMedGoogle Scholar
• Franssen R, Sankatsing RR, Hassink E et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler. Thromb. Vasc. Biol.29(9), 1336–1341 (2009).
   PubMed Web of Science ®Google Scholar
• Grover SA, Kaouache M, Joseph L, Barter P, Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch. Intern. Med.169(19), 1775–1780 (2009).
   PubMedGoogle Scholar
• Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Br. Med. J.338, b92 (2009).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Eng. J. Med.360, 859–873 (2009).
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R, Nordestgaard BG, Stene MCA et al. Association of loss of function mutations in the ABCA1 gene with high-density lipoproteon cholesterol levels and risk of ischemic heart disease. JAMA299(21), 2524–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Fazio S, Lincton MF. Elevated high-density levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. J. Clin. Endocrinol. Metab.94(4), 1081–1083 (2009).
   Google Scholar
• Alrasadi K, Awan K, Ruel I et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended release niacin (2 g). Am. J. Cardiol.102, 1341–1347 (2008).
   PubMed Web of Science ®Google Scholar